Compass Therapeutics appoints Bisker-Leib as CEO, Schuetz to President of R&D

Compass Therapeutics, Inc.

Vered Bisker-Leib appointed CEO effective Jan 9, 2024; salary increased to $600k, target bonus 55%.
Thomas Schuetz transitions from CEO to President of R&D and Vice Chair of Board.
Bisker-Leib receives options for 1,753,125 shares and RSUs for 1,753,125 shares at $1.93 exercise price.
Schuetz receives options for 637,500 shares and RSUs for 637,500 shares at $1.93.
Preliminary unaudited cash, equivalents and marketable securities approx $152M as of Dec 31, 2023.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Vered Bisker-Leib

Chief Executive Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2024-01-09
Filed: January 9, 2024, 6:59 PM ET

the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.

Role change

Thomas Schuetz

President of Research and Development

CMPX · Compass Therapeutics, Inc.

Effective: 2024-01-09
Successor: Vered Bisker-Leib
Filed: January 9, 2024, 6:59 PM ET

Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vered Bisker-Leib was appointed as Chief Executive Officer at Compass Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Schuetz changed role as President of Research and Development at Compass Therapeutics, Inc..

Action: transitioned
Role: President of Research and Development

Exact text from the filing

Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-000164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.